These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21417854)

  • 1. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.
    Spivak JL; Hasselbalch H
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):403-14. PubMed ID: 21417854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cutaneous side effects of a long-term treatment by hydroxyurea].
    Steels E; Heenen M; Germaux MA; Moens JP
    Rev Med Brux; 2006; 27(1):39-41. PubMed ID: 16608010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
    Olesen LH; Pedersen BB
    Ugeskr Laeger; 2001 Dec; 163(49):6908-11. PubMed ID: 11766504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea-induced amyopathic dermatomyositis presenting with heliotrope erythema.
    Ito E; Muro Y; Shibata A; Sugiura K; Akiyama M
    Dermatol Online J; 2014 Aug; 20(8):. PubMed ID: 25148281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
    Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
    Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible leg ulcer due to hydroxyurea in a case of chronic myeloid leukemia.
    Tripathi AK; Ahmad R; Sawlani KK
    J Assoc Physicians India; 2003 Oct; 51():1014-5. PubMed ID: 14719596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 66-year-old man with hydroxycarbamide induced pneumonitis.
    Derichs C; Klooster P; Vlasveld LT
    Neth J Med; 2018 Aug; 76(6):298-301. PubMed ID: 30152396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unusual dermatological toxicity of hydroxyurea in two dogs with spontaneously occurring tumours.
    Marconato L; Bonfanti U; Fileccia I
    J Small Anim Pract; 2007 Sep; 48(9):514-7. PubMed ID: 17617162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea: a key player in cancer chemotherapy.
    Madaan K; Kaushik D; Verma T
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):19-29. PubMed ID: 22149429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nail pigmentation due to hydroxycarbamide.
    Ceulen RP; Frank J; Poblete-Gutiérrez P
    Int J Dermatol; 2007 Nov; 46 Suppl 3():13-5. PubMed ID: 17973880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.
    Antonioli E; Guglielmelli P; Pieri L; Finazzi M; Rumi E; Martinelli V; Vianelli N; Luigia Randi M; Bertozzi I; De Stefano V; Za T; Rossi E; Ruggeri M; Elli E; Cacciola R; Cacciola E; Pogliani E; Rodeghiero F; Baccarani M; Passamonti F; Finazzi G; Rambaldi A; Bosi A; Cazzola M; Barbui T; Vannucchi AM;
    Am J Hematol; 2012 May; 87(5):552-4. PubMed ID: 22473827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.
    Internullo M; Giannelli V; Sardo L; Antonaglia C; Villani T; Angelici E; Palange P
    Eur Rev Med Pharmacol Sci; 2014; 18(2):190-3. PubMed ID: 24488907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and side effects of hydroxyurea used for primary thrombocythemia.
    Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F
    Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin lesion caused by hydroxyurea.
    Hirri HM; Green PJ
    Eur J Haematol; 2001; 67(5-6):328-9. PubMed ID: 11872082
    [No Abstract]   [Full Text] [Related]  

  • 15. Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related?
    Bader U; Banyai M; Böni R; Burg G; Hafner J
    Dermatology; 2000; 200(1):45-8. PubMed ID: 10681614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
    Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
    Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    Nielsen I; Hasselbalch HC
    Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical pharmacology of hydroxyurea].
    Góra-Tybor J; Robak T
    Acta Haematol Pol; 1995; 26(1):39-45. PubMed ID: 7747561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
    Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
    Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study.
    Ranjan N; Sharma NL; Shanker V; Mahajan VK; Tegta GR
    J Dermatolog Treat; 2007; 18(5):295-300. PubMed ID: 17852635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.